Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) in a report released on Sunday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Galmed Pharmaceuticals Stock Down 54.3 %

GLMD opened at $6.90 on Friday. The business’s fifty day simple moving average is $3.90 and its 200 day simple moving average is $4.14. Galmed Pharmaceuticals has a 52 week low of $2.73 and a 52 week high of $23.80. The stock has a market cap of $34.81 million, a PE ratio of -2.88 and a beta of 0.67.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.